Gezgin et al. showed that PRAME-specific T cells reacted against PRAME-positive uveal malignant melanoma cell lines, and approximately 45% of primary uveal malignant melanoma showed positive immunoreactivity for PRAME [33]. This evidence concerns the gene PRAME and uveal melanoma.